Previous Article | Next Article ![]()
Journal of Virology, January 2001, p. 351-361, Vol. 75, No. 1
Departments of Pediatric Infectious
Diseases,1
Neurology,2
Medicine,4 and Microbiology and
Immunology,6 University of Colorado Health
Sciences Center, and Denver Veterans Affairs Medical
Center,3 Denver, Colorado 80262, and
Department of Microbiology, College of Veterinary Medicine,
North Carolina State University, Raleigh, North Carolina
276065
Received 23 May 2000/Accepted 14 September 2000
Viral myocarditis is an important cause of human morbidity and
mortality for which reliable and effective therapy is lacking. Using
reovirus strain 8B infection of neonatal mice, a well-characterized experimental model of direct virus-induced myocarditis, we now demonstrate that myocardial injury results from apoptosis. Proteases play a critical role as effectors of apoptosis. The activity of the
cysteine protease calpain increases in reovirus-infected myocardiocytes and can be inhibited by the dipeptide alpha-ketoamide calpain inhibitor
Z-Leu-aminobutyric acid-CONH(CH2)3-morpholine
(CX295). Treatment of reovirus-infected neonatal mice with CX295
protects them against reovirus myocarditis as documented by (i) a
dramatic reduction in histopathologic evidence of myocardial injury,
(ii) complete inhibition of apoptotic myocardial cell death as
identified by terminal deoxynucleotidyltransferase-mediated dUTP-biotin
nick end labeling, (iii) a reduction in serum creatine phosphokinase, and (iv) improved weight gain. These findings are the first evidence for the importance of a calpain-associated pathway of apoptotic cell
death in viral disease. Inhibition of apoptotic signaling pathways may
be an effective strategy for the treatment of viral disease in general
and viral myocarditis in particular.
The mechanisms by which viruses
produce cytopathic effects in their host cells are not well understood.
Such knowledge is essential to an understanding of viral pathogenesis
and development of novel antiviral therapies. Apoptosis is a mechanism
of active cell death distinct from necrosis, characterized by DNA
fragmentation, cell shrinkage, and membrane blebbing without rupture
(26). Apoptosis plays a critical role in many physiologic
(28, 74), as well as infectious and noninfectious,
pathologic conditions (72). Viruses may either promote or
inhibit apoptosis as a strategy to maximize pathogenicity in their
hosts (40, 54, 67). Several viruses, including adenovirus,
poxviruses, herpesviruses, and human papillomavirus, proliferate and
evade host immune responses by interfering with programmed cell death
(1, 19, 31, 68). Many other viruses, such as human
immunodeficiency virus, human T-cell leukemia virus, influenza virus,
measles virus, rubella virus, poliovirus, human herpesvirus 6, Sindbis
virus, and reoviruses, cause cytopathic effect by induction of
apoptosis in their target cells (11, 14, 21-23, 34, 40, 42, 50,
70).
We have used reovirus-induced apoptosis as an experimental model system
to study the viral and cellular mechanisms involved in apoptotic cell
death (39). Reoviruses are nonenveloped viruses that
contain a genome of segmented, double-stranded RNA. Infection of
cultured fibroblasts and epithelial cells with reoviruses induces apoptosis. Reoviral strains differ in the efficiencies with which they
induce this cellular response, and these differences are determined by
the viral S1 gene (44, 69). Apoptosis also occurs following reovirus infection in vivo and colocalizes with areas of
pathologic injury (38, 39). This finding suggests that apoptosis is an important mechanism of tissue damage in reoviral infection.
Reovirus strain 8B is a reassortant reovirus that efficiently produces
myocarditis in infected neonatal mice (55, 58). Damage has
been shown to be a direct effect of viral infection of myocardiocytes
(60). This damage differs from that of several other
models of viral myocarditis (such as coxsackievirus and murine
cytomegalovirus) in which secondary inflammatory responses, or
lymphocyte recognition of viral or self-antigens on myocardial cells,
may be the predominant cause of cardiac damage (12, 17, 20, 30,
46). SCID mice infected with reovirus 8B develop myocarditis,
and passive transfer of reovirus-specific immune cells is protective,
rather than harmful, to 8B-infected mice (58, 60). This
finding indicates that immune mechanisms contribute to amelioration
rather than induction of reovirus-induced viral injury
(60). However, the mechanism by which direct myocardial injury occurs is not well characterized. Since tissue damage occurs by
apoptosis in other in vivo models of reoviral infection
(38), and apoptosis has been suggested in some models of
viral myocarditis (6, 25), we wished to determine if
reoviral myocarditis occurs as a result of apoptotic cell injury and,
if so, whether manipulation of known signaling pathways preceding
apoptosis is protective.
Protease cascades appear to play critical roles as effectors of
apoptosis, as with the cysteine proteases caspases and calpain (10, 32, 41, 62, 79). Caspases are the most extensively investigated members of this class of protease and have been implicated in a wide variety of apoptotic models. However, the role of calpain in
apoptosis has been recognized recently. Calpain is a calcium-dependent neutral cysteine protease that is ubiquitous in the cytosols of many
cell types (35, 63). Calpains have recently been
implicated in several models of apoptosis, including
dexamethasone-induced thymocyte apoptosis (65), neuronal
cell apoptosis (36), neutrophil apoptosis
(64), ischemia-induced rat liver apoptosis (27, 61), myonuclear apoptosis in limb-girdle dystrophy
(3), and chemical hypoxia-induced apoptosis of rat
myocytes (8). We have recently shown that reovirus-induced
apoptosis in vitro is preceded by increased cellular calpain activity
and is inhibited by two classes of calpain inhibitors
(13).
We now show that reovirus 8B-induced myocarditis occurs by apoptosis.
Calpain activity increases in cardiomyocytes following infection with
reovirus 8B, and calpain inhibition reduces myocardial injury and
morbidity in infected mice. This is evidence that interference with
apoptotic signaling pathways may prove of benefit as a therapeutic strategy in the treatment of viral infection in general and viral myocarditis in particular.
Virus.
Reovirus 8B is an efficiently myocarditic reovirus
that has been previously characterized (58). 8B stocks
were subjected to plaque assay three times and passaged twice in mouse
L cells prior to use.
Mice.
Swiss-Webster (Taconic) mouse litters were housed in
individual filter-topped cages in an American Association for
Laboratory Animal Care-accredited animal facility. All animal
procedures were performed under protocols approved by the appropriate
institutional committees.
Mouse inoculations.
Two-day-old Swiss-Webster (Taconic) mice
were intramuscularly inoculated with 1,000 PFU of 8B reovirus in the
left hind limb (20-µl volume). Mock-infected mice received gel saline
vehicle inoculation (equal volume) (137 mM NaCl, 0.2 mM
CaCl2, 0.8 mM MgCl2, 19 mM
H3BO3, 0.1 mM
Na2B4O7, 0.3% gelatin).
Histologic analysis.
At 7 days postinfection, mice were
sacrificed and hearts were immediately immersed in 10% buffered
formalin solution. After being mounted as transverse sections, hearts
were embedded in paraffin and sectioned to 6 µm in thickness. For
quantification of degree of myocardial injury, hematoxylin- and
eosin-stained midcardiac sections (at least six per heart) were
examined at a ×125 magnification by light microscopy and scored
blindly. Scoring was performed using a previously validated system
(58), with scores ranging from 0 to 4 (0, no lesions; 1, one or a few small lesions; 2, many small or a few large lesions; 3, multiple small and large lesions; and 4, massive lesions). Twenty-three
to 24 mice were scored from each group.
DNA fragmentation.
The presence of internucleosomal DNA
cleavage in myocardial tissue was investigated by phenol-chloroform
extraction of DNAs from 8B-infected and mock-infected hearts and
precipitation in 95% ethyl alcohol. The DNA was then end labeled with
5 µCi of [32P]dGTP using 10 U of terminal transferase
(M187; Promega Corporation), resolved by electrophoresis on a 2%
agarose gel, fixed in 5% acetic acid-5% methanol, dried, and scanned
on a Instant Imager (Packard Instrument Company).
TUNEL.
Evaluation of fragmented DNA was performed by
terminal deoxynucleotidyltransferase (TdT)-mediated dUTP-biotin nick
end labeling (TUNEL), as previously described (38).
Paraffin-embedded cardiac midsections were prepared by removing
paraffin with xylene and then rehydrating them in 100, 95, and then
70% ethanol solutions. After digestion in proteinase K solution
(Boehringer Mannheim) for 30 min at 37°C, slides were pretreated in
0.3% H2O2 in phosphate-buffered saline for 15 min at room temperature and then washed. The TdT labeling reaction was
carried out under coverslips in a humidified chamber for 1 h at
37°C with TdT and digoxigenin 11-dUTP. (Boehringer Mannheim). The
reaction was stopped with SSC (1× SSC is 0.15 M NaCl plus 0.015 M
sodium citrate) buffer. After being blocked in 2% bovine serum albumin
for 10 min, sections were probed with Vectastain ABC (avidin DH and
biotinylated enzyme; Vector Laboratories) for 1 h at room
temperature, and then visualized with a diaminobenzadine peroxidase
substrate kit (Vector Laboratories). Negative and positive controls
were used with all reactions.
Viral-antigen stain.
Cardiac midsections were prepared as
noted above. Following the hydrogen peroxide incubation, slides were
blocked in 2% normal goat serum for 30 min at room temperature.
Sections were then incubated in rabbit polyclonal anti-reovirus type 3 Dearing antiserum as the primary antibody (gift of Terence Dermody,
Vanderbilt University) at a dilution of 1:1,000 for 1 h at 37°C.
Biotinylated goat anti-rabbit antibody was used as the secondary
antiserum (1:200 dilution in 2% normal goat serum) for 30 min at
37°C. Sections were probed and visualized as noted above.
Calpain activity in myocytes.
The determination of the
presence of calpain-specific spectrin (fodrin) breakdown products (150- and 145-kDa doublet) by immunoblotting was used as an assay of calpain
activity (36). Mouse primary cardiac myocyte cultures were
prepared as previously described (5). Cells were plated at
1.6 × 106 cells/well in 24-well plates and incubated
for 48 h. Cells were then infected with reovirus strain 8B
(multiplicity of infection [MOI], 20, in Dulbecco modified Eagle
medium [DMEM]) or mock infected (DMEM) and then incubated at 37°C.
Mock-infected cells were harvested at 48 h. 8B-infected cells were
harvested at 24, 48, and 72 h postinfection. Cell lysates were
prepared by sonication in lysis buffer (15 mM Tris [pH 7.4], 10 mM
EDTA, 0.1% NP-40, 20% glycerol, 50 mM
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.1.351-361.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Calpain Inhibition Protects against Virus-Induced
Apoptotic Myocardial Injury
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-mercaptoethanol, 50 µg of
pepstatin per ml, 100 µg of leupeptin per ml, 1 mM
phenylmethylsulfonyl fluoride), and the cytoplasmic fractions were run
on a 7.5% polyacrylamide gel. Protein loading for these gels (25 µg/well) was normalized by protein concentration analysis of cell
lysates. Following transfer (15 V overnight), the nitrocellulose
membrane was blocked in 5% nonfat dried milk-Tris normal saline for
2 h, probed with anti-fodrin mouse monoclonal antibody (ICN) at a
dilution of 1:1,000 for 1.5 h, and then washed. Membranes were
then incubated in anti-mouse immunoglobulin G horseradish
peroxidase-linked whole antibody (Amersham) at a dilution of 1:1,000,
as the secondary antibody. After the membranes were washed, ECL Plus
(Amersham) was used for detection.
Specificity of the calpain inhibitor CX295. Z-Leu-aminobutyric acid- CONH(CH2)3-morpholine (CX295) is a dipeptide alpha-ketoamide compound which inhibits calpain at the active site (kindly provided by Gary Rogers at Cortex Pharmaceuticals, Inc.). To determine the efficacy of CX295 as a calpain inhibitor, 10 µg of purified µ-calpain (porcine RBC; Calbiochem) was added to the preferred fluorogenic calpain substrate sucrose-Leu-Tyr-amino-methyl-coumarin (SLY-AMC) in the presence and absence of CX295 (100 µM), as well as in the presence of the pan-caspase inhibitor Z-D-DCB (100 µM). The calpain assay was performed as previously described (16). Proteolytic hydrolysis of the substrate by purified calpain liberates the highly fluorescent AMC moiety. Fluorescence at a 380-nm excitation and 460-nm emission was quantified with a Hitachi F2000 spectrophotometer. An AMC standard curve was determined for each experiment. Calpain activity was expressed in picomoles of AMC released per minute of incubation time per microgram of purified calpain.
To determine the specificity of CX295 as a calpain inhibitor, 10 ng of purified caspase 3 (Upstate) was added to the preferred fluorogenic caspase-3 substrate DEVD-AMC in the presence and absence of the pan-caspase inhibitor Z-D-DCB (100 µM), as well as CX295 (100 µM). In addition, 57 ng of purified caspase-1 (provided by Nancy Thornberry, Merck) was added to the preferred fluorogenic caspase-1 substrate YVAD-AMC in the presence and absence of Z-D-DCB, as well as CX295. The caspase activity assay was performed as previously described (16). Caspase activity was expressed as picomoles of AMC released per minute of incubation time per nanogram of purified caspase. Experiments were all performed in triplicate.Calpain inhibition in vivo. For calpain inhibition experiments, animals received daily intraperitoneal injections of either active CX295 (70 mg/kg of body weight in a 50-µl volume) or its inactive saline diluent. The first dose was given 30 min prior to infection with 8B virus. A total of six doses were given, at 24-h intervals. Mice were sacrificed at 7 days postinfection.
Viral titer determination.
Injected hind limbs and whole
hearts were placed in 1 ml of gel saline and immediately frozen at
70°C. After three freeze (
70°C)-thaw (37°C) cycles, the
tissues were sonicated approximately 15 to 30 s by using a
microtip probe (Heat Systems model XL2020) until a homogenous solution
was obtained. The virus suspensions were serially diluted in 10-fold
steps in gel saline and placed in duplicate on L-cell monolayers for
plaque assay, as previously described (13). Virus titers
were expressed as log10 PFU per milliliter.
Serum CPK. Following decapitation of mice, whole blood was collected from individual mice into plasma separator tubes with lithium heparin to prevent coagulation (Microtainer; Becton Dickinson). Samples were collected from 8B-infected mice treated with CX295 (n = 20), 8B-infected mice treated with the inactive diluent (n = 20), and uninfected age-matched controls (n = 9). Serum creatine phosphokinase (CPK) measurements were performed by the University of Colorado Health Sciences Center Clinical Laboratory and were expressed as units per liter.
Growth. Mice were infected with 10 PFU of 8B reovirus. Infected drug-treated (n = 15) and infected control (n = 15) mice were weighed daily on days 0 to 14 postinfection. Additional experiments using a higher dose of virus (1,000 PFU) were also completed, with daily weighing on days 0 to 7 postinfection. In these experiments, weights were also compared to those of normal age-matched uninfected mice.
Statistics. The results of all experiments are reported as means ± standard errors of the means. Means were compared using parametric two-tailed t tests (Graph Pad; Prism), and differences were considered significant if P values were <0.05.
| |
RESULTS |
|---|
|
|
|---|
(i) Reovirus 8B induces myocardial injury by apoptosis.
Mice
were inoculated intramuscularly into the hind limb with either 1,000 PFU of strain 8B reovirus or gel saline (mock infection). At 7 days
postinfection, mice were sacrificed and transverse cardiac sections
were prepared for histologic evaluation. In the 8B-infected hearts,
there was marked myocardial disruption and diffuse edema (Fig.
1B). Numerous pyknotic nuclei and
apoptotic bodies were present (Fig. 1B; see also Fig. 5E). Despite the
degree of myocardial injury, only rare mononuclear cells (predominantly
macrophages) and neutrophils were present. Myocardial disruption and
edema were not seen in mock-infected hearts (Fig. 1A). Extensive areas of apoptotic TUNEL-positive nuclei were noted in the 8B-infected hearts
(Fig. 1D), which correlated with the areas of histologic abnormality
described above. Mock-infected hearts were TUNEL negative (Fig. 1C).
Large regions of reovirus antigen-positive tissue were noted in the
8B-infected hearts (Fig. 1F) and occurred in the same distribution as
the areas of histologic injury and TUNEL-positive cells.
|
|
(ii) Calpain is activated in 8B-infected murine cardiac
myocytes.
We have previously shown that reovirus infection in L929
cells results in increased calpain activity, which precedes apoptosis (13). We wished to determine whether calpain activity was
also increased in myocardial cells following reovirus infection.
Proteolysis of spectrin (fodrin), a preferred calpain substrate, was
examined as an indication of calpain activation. Intact spectrin (280 kDa) is degraded by calpain, resulting in a characteristic spectrin breakdown product doublet seen at 150 and 145 kDa. Mouse primary cardiac myocyte cultures were infected with reovirus strain 8B (MOI,
20) or mock infected. Lysates were prepared after harvesting of cells
at 24, 48, and 72 h postinfection. Western blot analysis of these
cytoplasmic fractions revealed increased calpain activity following 8B
infection compared to that of mock-infected cytoplasmic fractions. This
increase was first detectable at 24 h, reached maximal intensity
by 48 h, and was still present at 72 h postinfection (Fig.
3A). Densitometric analysis of
calpain-specific breakdown products revealed a peak fourfold increase
in calpain activity following virus infection (Fig. 3B). Caspase
degradation of spectrin results in breakdown products at 120 kDa, which
were not observed in this experiment. These data demonstrate that an
increase in calpain activity occurs following infection of
myocardiocytes with reovirus strain 8B, in a time course that parallels
the onset of apoptosis.
|
(iii) CX295 is an effective calpain inhibitor and does not
appreciably inhibit caspases.
Based on our findings that (i)
8B-induced myocarditis is due to apoptosis, (ii) calpain is activated
in 8B-infected myocardiocytes, and (iii) inhibition of calpain
activation inhibits reovirus-induced apoptosis in vitro, we wished to
determine if calpain inhibition could prevent 8B-induced myocardial
injury in vivo. CX295 is a dipeptide alpha-ketoamide compound that
inhibits calpain at the active site and is nontoxic and effective in
vivo (4, 48). To confirm the specificity of the compound,
the activity of purified calpain was monitored in the presence and
absence of CX295. The inactive diluent of CX295 and the pan-caspase
inhibitor Z-D-DCB were used as controls.
Purified calpain activity (measured as cleavage of SLY-AMC) was
markedly reduced by CX295 (Fig. 4A). Calpain activity was decreased from 1,255 ± 22 to 206 ± 4 pmol/min/µg in the presence of CX295 (P < 0.0001).
Neither the diluent nor Z-D-DCB controls had
appreciable effect on calpain activity.
|
(iv) Calpain inhibitor CX295 inhibits 8B-induced myocardial injury. Two-day-old Swiss-Webster mice were infected with 1,000 PFU of 8B virus and received six daily intraperitoneal injections of either active CX295 (70 mg/kg) or its inactive saline diluent as a control (see Materials and Methods). Mice were sacrificed on day 7 postinfection, and myocardial sections were prepared.
Transverse cardiac sections from 8B-infected mice treated with CX295 or its inactive diluent (control) were stained with hematoxylin and eosin and viewed by light microscopy (Fig. 5A to F). Cardiac tissue from control mice (Fig. 5A) showed extensive focal areas of myocardial damage, which were absent in the CX295-treated animals, despite identical viral infection (Fig. 5B). Marked disruption of the normal myocardial architecture was evident in hearts of control mice (Fig. 5C), compared to that of drug-treated animals (Fig. 5D). Nuclei with apoptotic morphology were easily seen within these areas in the control mice (Fig. 5E), including in cells with condensed and pyknotic nuclei, as well as apoptotic bodies. These characteristics were absent in the drug-treated animals (Fig. 5F). Staining by TUNEL of comparable sections from drug-treated and diluent-treated (control) infected mice was examined. Nuclei that stained positive by TUNEL were virtually absent in the drug-treated mice (Fig. 5H), unlike with control infected animals (Fig. 5G).
|
|
|
|
|
| |
DISCUSSION |
|---|
|
|
|---|
Viral myocarditis remains a serious disease without reliable or effective treatment. The events following viral attachment and replication in myocardial tissue that lead to myocarditis are not clearly understood. A variety of mechanisms from various models have been suggested, including direct viral injury and persistence (9, 24), autoimmune phenomena (17, 45, 51), cytokine fluxes (18, 33, 52, 59), inflammation (29, 53), and apoptosis (12, 77, 78). A clearer understanding of pathogenic mechanisms is crucial for the development of effective therapeutic strategies, since currently employed antiviral agents have not made a significant impact on outcomes from this clinical syndrome. Reoviral myocarditis is an ideal model with which to study these events, since myocardial injury is a direct effect of virus infection and does not involve immune-mediated effects.
Reovirus 8B induces myocarditis by apoptosis.
Reovirus 8B
induces myocarditis in mice by direct viral injury to myocytes, and we
now show that this occurs by induction of apoptosis. This conclusion is
supported by the presence of distinctive morphologic criteria upon
microscopic examination of infected heart tissues; TUNEL-positive
nuclei were found exclusively in regions of viral infection and
myocardial injury. The presence of apoptosis was confirmed by the
presence of the characteristic intranucleosomal cleavage pattern of
extracted DNA. It has been shown previously that multiple viral genes
(M1, L1 and L2, and S1) encoding core and attachment proteins are
determinants of reovirus-induced acute myocarditis (56).
Interactions between these proteins determine myocarditic potential.
Several of these genes have been associated with reovirus RNA synthesis
and reovirus induction of and sensitivity to beta interferon in cardiac
myocyte cultures, which are determinants of reovirus myocarditic
potential. In addition, the S1 gene, which codes for the viral
attachment protein
1, is the primary determinant of apoptotic
potential among strains of reovirus (69). It is likely,
therefore, that the extent of reovirus-induced myocardial injury is
determined by a combination of host responses, encompassing both the
interferon and the apoptosis pathways. Indeed, just as inhibition of
the interferon pathway was sufficient to enhance reovirus-induced myocarditis (59), we show here that inhibition of the
apoptotic pathway is sufficient to abrogate reovirus-induced
myocarditis. Thus, apoptosis is an integral component of
reovirus-induced myocardial injury.
Calpain activity is increased in reovirus-infected myocardiocytes, and calpain inhibition is protective against reovirus-induced myocarditis. Calpain is a calcium-activated cysteine protease that has proven importance with regard to the initiation of apoptosis in the reoviral model, as well as several other unrelated models of apoptosis (see the introduction). We first demonstrated that calpain activity is increased in cardiac myocytes in vitro following 8B infection, in a time course paralleling induction of apoptosis. We then demonstrated that calpain inhibition resulted in a reduction of calpain activity in infected cells and dramatic reductions in reovirus-induced injury, as well as apoptosis. Clinically significant reduction in myocardial injury was documented by reduced serum CPK levels and improved growth in treated mice.
It is likely that CX295 acted primarily by interfering with crucial signal transduction cascades involving calpain, required for induction of apoptotic cell death. Additionally, it is possible that CX295 provided some portion of its effect by inhibiting viral growth at either the primary (hind limb) or secondary (heart) site of replication, since viral titers were slightly lower in drug-treated animals than in controls. Slight reductions in viral titer do not seem a likely explanation for the majority of drug effect, since in prior experiments involving reovirus-induced myocarditis, yields of virus at early and late times postinfection did not correlate with the degree of myocardial injury (57). In addition, efficiently myocarditic and poorly myocarditic reovirus strains replicate to similar titers in the heart; thus, differences in myocarditic potential do not simply reflect viral growth in the heart (56). One must be cautious in attributing a role for calpain in disease pathogenesis based solely on data derived from calpain inhibition. Currently available calpain inhibitors suitable for in vivo use have weak, but measurable, inhibitory activities against other cysteine proteases. However, the inhibitor employed in our experiments, CX295, is 500- to 900-fold more active against calpains than cathepsins (the Ki for calpain is 0.027
0.042 µM,
versus a Ki for cathepsin B of 24 µM) and
failed to inhibit caspase activity in vitro, as described in this
paper. We believe that inhibition of calpain, rather than of other
cysteine proteases, is the essential element of CX295's protective
effect against 8B-induced myocardial apoptosis and injury.
It is not clear what constitutes the upstream and downstream components
of a signaling cascade within which calpain might fit, either during
reovirus infection or in other systems where calpain is involved. The
mechanisms by which reovirus triggers increased cellular calpain
activity are not known but may include initiation of calcium fluxes
following viral attachment, as demonstrated with rotavirus, a closely
related virus (15); upregulation of growth factors which
facilitate calpain activation (37, 66); or upregulation of
endogenous calpain activator proteins which have been characterized for
several cell types (49). Calpain may play a physiologic
role in the regulation of a variety of cellular transcription factors
and cell cycle-regulating factors implicated in apoptosis, including
Jun, Fos, p53, cyclin D, and NF-
B (3, 7, 73). We have
recently shown that activation of NF-
B is required for
reovirus-induced apoptosis (J. L. Connolly, S. E. Rodgers, B. Pike, P. Clarke, K. L. Tyler, and T. S. Dermody, Abstr. 17th
Ann. Meet. Am. Soc. Virology, abstr. 17-2, 1998), suggesting the
possibility that calpain inhibition acts to modulate NF-
B-induced
signal transduction. Calpains may also modulate cell death by cleaving
Bax, a proapoptotic protein located in the cytosol (75).
In addition, the caspase and calpain proteolytic cascades may interact.
Caspases may play a role in the regulation of calpain by cleavage of
calpastatin, the endogenous inhibitor of calpain (43, 71,
76). Reflexively, calpain may be involved in the proteolytic
activation of some caspases (47).
Potential therapeutic efficacy of calpain inhibitors. In conclusion, our data suggest that reovirus-induced myocarditis occurs by direct viral induction of apoptotic cell death and that injury can be markedly reduced with the use of a calpain inhibitor. To our knowledge, this is the first successful demonstration of the use of calpain inhibition in vivo to ameliorate myocarditis in particular and virus-induced disease in general. However, future experiments are needed to determine whether calpain inhibition remains effective when it is administered after the onset of viral infection. Our results demonstrate the utility of apoptosis inhibition as a strategy for protection against viral infection.
| |
ACKNOWLEDGMENTS |
|---|
We thank Gary Rogers of Cortex Pharmaceutical for providing the calpain inhibitor CX295 and its inactive diluent. The University of Colorado Cancer Center provided core tissue culture and medium facilities.
This work was supported by Public Health Service grant 1RO1AG14071 from the National Institute of Aging, Merit and REAP grants from the Department of Veterans Affairs, a U.S. Army Medical Research and Material Command grant (USAMRMC 98293015) (K.L.T.), a Young Investigator Award from the National Kidney Foundation (C.L.E.), Public Health Service grant 1RO1HL57161, and North Carolina State University College of Veterinary Medicine grant 204743 (B.S.).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Neurology (B-182), University of Colorado Health Sciences Center, 4200 E. 9th Ave., Denver, CO 80262. Phone: (303) 393-2874. Fax: (303) 393-4686. E-mail: Ken.Tyler{at}UCHSC.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Aubert, M., and J. A. Blaho.
1999.
The herpes simplex virus type 1 regulatory protein ICP27 is required for the prevention of apoptosis in human cells.
J. Virol.
73:2803-2813 |
| 2. |
Bachmeir, K.,
J. Mair,
F. Offner,
C. Pummerer, and N. Neu.
1995.
Serum cardiac troponin T and creatine kinase-MB elevations in murine autoimmune myocarditis.
Circulation
92:1927-1932 |
| 3. |
Baghdiguian, S.,
M. Martin,
I. Richard,
F. Pons,
C. Astier,
N. Bourg,
R. T. Hay,
R. Chemaly,
G. Haleby,
J. Loiselet,
L. V. Anderson,
A. Lopez de Muvigin,
M. Fardeu,
P. Mangeat,
J. S. Beckmann, and G. Lefranc.
1999.
Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the I B /NF-KB pathway in limb-girdle muscular dystrophy type 2A.
Nat. Med.
5:503-511[CrossRef][Medline].
|
| 4. | Bartus, R. T., K. L. Baker, A. D. Heiser, S. D. Sawyer, R. L. Dean, P. J. Elliott, and J. A. Straub. 1994. Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage. J. Cerebr. Blood Flow Metab. 14:537-544[Medline]. |
| 5. |
Baty, C. J., and B. Sherry.
1993.
Cytopathogenic effect in cardiac myocytes but not in cardiac fibroblasts is correlated with reovirus-induced myocarditis.
J. Virol.
67:6295-6298 |
| 6. | Bowles, N. E., and J. A. Towbin. 1998. Molecular aspects of myocarditis. Curr. Opin. Cardiol. 13:179-184[Medline]. |
| 7. |
Chen, F.,
Y. Lu,
D. C. Kuhn,
M. Maki,
X. Shi, and L. M. Demers.
1997.
Calpain contributes to silica-induced IKB-degradation and nuclear factor B activation.
Arch. Biochem. Biophys.
34:383-388.
|
| 8. | Chen, S. J., M. E. Bradley, and T. C. Lee. 1998. Chemical hypoxia triggers apoptosis of cultured neonatal rat cardiac myocytes: modulation by calcium-regulated proteases and protein kinases. Mol. Cell. Biochem. 178:141-149[CrossRef][Medline]. |
| 9. | Chow, L. H., K. W. Beisel, and B. M. McManus. 1992. Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viral pathogenesis of myocardial injury. Lab. Investig. 66:24-31[Medline]. |
| 10. | Cohen, G. M. 1997. Caspases: the executioners of apoptosis. Biochem. J. 326:1-16. |
| 11. |
Colamussi, M. L.,
M. R. White,
E. Crouch, and K. L. Hartshorn.
1999.
Influenza A virus accelerates neutrophil apoptosis and markedly potentiates apoptotic effects of bacteria.
Blood
93:2395-2403 |
| 12. |
Colston, J. T.,
B. Chandrasakar, and G. L. Freeman.
1998.
Expression of apoptosis-related proteins in experimental coxsackie myocarditis.
Cardovasc. Res.
38:158-168 |
| 13. |
DeBiasi, R. L.,
M. K. T. Squier,
B. Pike,
M. Wynes,
T. S. Dermody, and K. L. Tyler.
1999.
Reovirus-induced apoptosis is preceded by increased cellular calpain activity and is blocked by calpain inhibitors.
J. Virol.
73:695-701 |
| 14. | Dockrell, D. H., A. D. Badley, J. S. Villacian, C. J. Heppelman, A. Algeciras, S. Ziesvnar, H. Yagita, D. H. Lynch, P. C. Roche, P. J. Leibson, and C. V. Paya. 1998. The expression of Fas ligand by macrophages and its upregulation by human immunodeficiency virus infection. J. Clin. Investig. 101:2394-2405[Medline]. |
| 15. |
Dong, Y.,
C. Q. Zeng,
J. M. Ball,
M. K. Estes, and A. P. Morris.
1997.
The rotavirus enterotoxin NSP4 mobilizes calcium in human intestinal cells by stimulating phospholipase C-mediated inositol 1,4,5-triphosphate production.
Proc. Natl. Acad. Sci. USA
94:3960-3965 |
| 16. | Edelstein, C. L., H. Ling, P. E. Gengaro, R. A. Nemenoff, B. A. Bahr, and R. W. Schrier. 1997. Effect of glycine on prelethal and postlethal increases in calpain activity in rat renal proximal tubules. Kidney Int. 52:1271-1278[Medline]. |
| 17. | Fairweather, D., C. M. Lawson, A. J. Chapman, C. M. Brown, T. W. Booth, J. M. Papadimitriou, and G. R. Snellam. 1998. Wild isolates of murine cytomegalovirus induce myocarditis and antibodies that cross-react with virus and cardiac myosin. Immunology 94:263-270[CrossRef][Medline]. |
| 18. | Freeman, G. L., J. T. Colston, M. Zabalgoitia, and B. Chandrasekar. 1998. Contractile depression and expression of proinflammatory cytokines and iNOS in viral myocarditis. Am. J. Physiol. 274:H249-H258. |
| 19. |
Galvan, V.,
R. Brandimarti, and B. Roizman.
1999.
Herpes simplex virus 1 blocks caspase-3-independent and caspase-dependent pathways to cell death.
J. Virol.
73:3219-3226 |
| 20. | Gauntt, C. J. 1997. Roles of the humoral response in coxsackievirus B-induced disease. Curr. Top. Microbiol. Immunol. 223:259-282[Medline]. |
| 21. |
Girard, S.,
T. Couderc,
J. D. Destombes,
J. Thiesson,
F. Delpeyroux, and B. Blondel.
1999.
Poliovirus induces apoptosis in the mouse central nervous system.
J. Virol.
73:6066-6072 |
| 22. | Ichimi, R., T. Jin-o, and M. Ito. 1999. Induction of apoptosis in cord blood lymphocytes by HHV-6. J. Med. Virol. 58:63-68[CrossRef][Medline]. |
| 23. | Jaworski, A., and S. M. Crowe. 1999. Does HIV cause depletion of CD4+ T cells in vivo by the induction of apoptosis? Immunol. Cell Biol. 77:90-98[CrossRef][Medline]. |
| 24. | Kanda, T., H. Koike, M. Arai, J. E. Wilson, C. M. Carthy, D. Yang, B. M. McManus, R. Nagai, and I. Kobayashi. 1999. Increased severity of viral myocarditis in mice lacking lymphocyte maturation. Int. J. Cardiol. 68:13-22[CrossRef][Medline]. |
| 25. |
Kawai, C.
1999.
From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future.
Circulation
99:1091-1100 |
| 26. | Kerr, J. F. R., A. H. Wylie, and A. R. Currie. 1972. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26:239-257[Medline]. |
| 27. | Kohli, V., J. F. Madden, R. C. Bentley, and P. A. Clavien. 1999. Calpain mediates ischemic injury of the liver through modulation of apoptosis and necrosis. Gastroenterology 116:168-178[CrossRef][Medline]. |
| 28. | Krammer, P. H., I. Behrmann, P. Daniel, J. Dhein, and K. M. Debatin. 1994. Regulation of apoptosis in the immune system. Curr. Opin. Immunol. 6:276-289. |
| 29. | Lee, J. K., S. H. Zaidi, P. Liu, F. Dawood, A. Y. Cheah, W. H. Wen, Y. Saiki, and M. Rabinovitch. 1998. A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced murine myocarditis. Nat. Med. 4:1383-1391[CrossRef][Medline]. |
| 30. | Liu, P., T. Martino, M. A. Opavsky, and J. Penninger. 1996. Viral myocarditis: balance between viral infection and immune response. Can. J. Cardiol. 12:935-943[Medline]. |
| 31. |
Marshall, W. L.,
C. Yim,
E. Gustafson,
T. Graf,
D. R. Sage,
K. Hanify,
L. Williams,
J. Fingeroth, and R. W. Finberg.
1999.
Epstein-Barr virus encodes a novel homolog of the bcl-2 oncogene that inhibits apoptosis and associates with Bax and Bak.
J. Virol.
73:5181-5185 |
| 32. | Martin, S. J., and D. R. Green. 1995. Protease activation during apoptosis: death by a thousand cuts? Cell 82:349-352[CrossRef][Medline]. |
| 33. | Matsumori, A. 1996. Cytokines in myocarditis and cardiomyopathies. Curr. Opin. Cardiol. 11:302-309[CrossRef][Medline]. |
| 34. | Megyeri, K., K. Berencsi, T. D. Halazonetis, G. C. Prendergast, G. Gri, S. A. Plotkin, G. Rovera, and E. Gonczol. 1999. Involvement of a p53-dependent pathway in rubella virus-induced apoptosis. Virology 259:74-84[CrossRef][Medline]. |
| 35. | Murachi, T. 1983. Calpain and calpastatin. Trends Biochem. Sci. 8:167-169[CrossRef]. |
| 36. |
Nath, R.,
K. J. Raser,
D. Stafford,
I. Hajimohammadreza,
A. Posner,
H. Allen,
R. V. Talanian,
P. Yuen,
R. B. Gilbertsen, and K. K. Wang.
1996.
Non-erythroid -spectrin breakdown by calpain and interleukin 1 B-converting-enzyme-like protease(s) in apoptotic cells: contributory roles of both protease families in neuronal apoptosis.
Biochem. J.
319:686-690.
|
| 37. | Neuberger, T., A. K. Chakrabarti, T. Russell, G. H. DeVreis, E. L. Hogan, and N. L. Banik. 1997. Immunolocalization of cytoplamic and myelin mCalpain in transfected Schwann cells. I. Effect of treatment with growth factors. J. Neurosci. Res. 47:521-530[CrossRef][Medline]. |
| 38. | Oberhaus, S. M., R. L. Smith, G. H. Clayton, T. S. Dermody, and K. L. Tyler. 1997. Reovirus infection and tissue injury in the mouse central nervous system are associated with apoptosis. J. Virol. 71:2100-2106[Abstract]. |
| 39. | Oberhaus, S. M., T. S. Dermody, and K. L. Tyler. 1998. Apoptosis and the cytopathic effects of reovirus. Curr. Top. Microbiol. Immunol. 233:23-49[Medline]. |
| 40. | O'Brien, V. 1998. Viruses and apoptosis. J. Gen. Virol. 79:1833-1834[Medline]. |
| 41. | Patel, T., G. J. Gores, and S. H. Kaufmann. 1996. The role of proteases during apoptosis. FASEB J. 10:587-597[Abstract]. |
| 42. | Pignata, C., M. Fiore, S. deFilippo, M. Cavalcanti, L. Gaetaniello, and I. Scotese. 1998. Apoptosis as a mechanism of peripheral blood mononuclear cell death after measles and varicella-zoster virus infections in children. Pediatr. Res. 43:77-83[Medline]. |
| 43. | Porn-Ares, M. I., A. Samali, and S. Orenius. 1998. Cleavage of the calpain inhibitor, calpastatin, during apoptosis. Cell Death Differ. 5:1028-1033[CrossRef][Medline]. |
| 44. | Rodgers, S. E., E. S. Barton, S. M. Oberhaus, B. Pike, C. A. Gibson, K. L. Tyler, and T. S. Dermody. 1997. Reovirus-induced apoptosis of MDCK cells is not linked to viral yield and is blocked by Bcl-2. J. Virol. 71:2540-2546[Abstract]. |
| 45. | Rose, N. R., A. Herskowitz, and D. A. Neumann. 1993. Autoimmunity in myocarditis: models and mechanisms. Clin. Immunol. Immunopathol. 68:95-99[CrossRef]. |
| 46. | Rose, N. R., and S. L. Hill. 1996. The pathogenesis of postinfectious myocarditis. Clin. Immunol. Immunopathol. 80:S92-S99[CrossRef][Medline]. |
| 47. | Ruiz-Vela, A., G. Gonzalez de Buitrago, and A.-C. Martinez. 1999. Implication of calpain in caspase activation during B cell clonal deletion. EMBO J. 18:4988-4998[CrossRef][Medline]. |
| 48. |
Saatman, K. E.,
H. Murai,
R. T. Bartus,
D. H. Smith,
N. J. Hayward,
B. R. Perri, and T. K. McIntosh.
1996.
Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat.
Proc. Natl. Acad. Sci. USA
93:3428-3433 |
| 49. | Salamino, F., R. DeTullio, P. Mengotti, P. L. Viotti, E. Melloni, and S. Pontremoli. 1993. Site-directed activation of calpain is promoted by a membrane-associated natural activator protein. Biochem. J. 290:191-197. |
| 50. | Schultz-Cherry, S., and V. S. Hinshaw. 1996. Influenza virus neuraminidase activates latent transforming growth factor beta. J. Virol. 70:8624-8629[Abstract]. |
| 51. | Schwimmbeck, P. L., S. A. Huber, and H. P. Schultheiss. 1997. Roles of T cells in coxsackie-B induced disease. Curr. Top. Microbiol. Immunol. 223:283-303[Medline]. |
| 52. | Seko, Y., N. Takahashi, H. Yagita, K. Okumura, and Y. Yazaki. 1997. Expression of cytokine mRNA's in murine hearts with acute myocarditis caused by coxsackievirus b3. J. Pathol. 183:105-108[CrossRef][Medline]. |
| 53. |
Seko, Y.,
N. Takahashi,
M. Azuma,
H. Yagita,
K. Okumura, and Y. Yazaki.
1998.
Expression of costimulatory molecule CD40 in murine heart with acute myocarditis and reduction of inflammation by treatment with anti-CD40L/B7-1 monoclonal antibodies.
Circ. Res.
83:463-469 |
| 54. | Shen, Y., and T. E. Shenk. 1995. Viruses and apoptosis. Curr. Opin. Genet. Dev. 5:105-111[CrossRef][Medline]. |
| 55. | Sherry, B. 1998. Pathogenesis of reovirus myocarditis, p. 51-66. In K. L. Tyler, and M. B. A. Oldstone (ed.), Reoviruses II: cytopathogenicity and pathogenesis. Springer-Verlag, Berlin, Germany. |
| 56. | Sherry, B., and M. A. Blum. 1994. Multiple viral core proteins are determinants of reovirus-induced acute myocarditis. J. Virol. 63:8461-8465. |
| 57. |
Sherry, B.,
C. J. Baty, and M. A. Blum.
1996.
Reovirus-induced acute myocarditis in mice correlates with viral RNA synthesis rather than generation of infectious virus in cardiac myocytes.
J. Virol.
70:6709-6715 |
| 58. |
Sherry, B.,
F. J. Schoen,
E. Wenske, and B. N. Fields.
1989.
Derivation and characterization of an efficiently myocarditic reovirus variant.
J. Virol.
63:4840-4849 |
| 59. |
Sherry, B.,
J. Torres, and M. A. Blum.
1998.
Reovirus induction of and sensitivity to beta interferon in cardiac myocyte cultures correlate with induction of myocarditis and are determined by viral core proteins.
J. Virol.
72:1314-1323 |
| 60. |
Sherry, B.,
X.-Y. Li,
K. L. Tyler,
J. M. Cullen, and H. W. Virgin.
1993.
Lymphocytes protect against and are not required for reovirus-induced myocarditis.
J. Virol.
67:6119-6124 |
| 61. | Sindram, D., V. Kohli, J. F. Madden, and P. A. Clavien. 1999. Calpain inhibition prevents sinusoidal endothelial cell apoptosis in the cold ischemic rat liver. Transplantation 68:136-140[CrossRef][Medline]. |
| 62. | Solary, E., B. Eymin, N. Droin, and M. Haugg. 1998. Proteases, proteolysis, and apoptosis. Cell Biol. Toxicol. 14:11-32. |
| 63. | Sorimachi, H., S. Ishiura, and K. Suzuki. 1997. Structure and physiological function of calpains. Biochem. J. 328:721-732. |
| 64. | Squier, M. K., A. J. Sehnert, K. S. Sellins, A. M. Malkinson, E. Takanoand, and J. J. Cohen. 1999. Calpain and calpastatin regulate neutrophil apoptosis. J. Cell. Physiol. 178:311-319[CrossRef][Medline]. |
| 65. | Squier, M. K. T., and J. J. Cohen. 1997. Calpain, an upstream regulator of thymocyte apoptosis. J. Immunol. 158:3690-3697[Abstract]. |
| 66. | Strong, J. E., D. Tang, and P. W. K. Lee. 1993. Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency. Virology 197:405-411[CrossRef][Medline]. |
| 67. | Teodoro, J. G., and P. E. Branton. 1997. Regulation of apoptosis by viral gene products. J. Virol. 71:1739-1746[Medline]. |
| 68. | Thomas, M., and L. Banks. 1999. Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J. Gen. Virol. 80:1513-1517[Abstract]. |
| 69. |
Tyler, K. L.,
M. K. T. Squier,
S. E. Rodgers,
B. E. Schneider,
S. M. Oberhaus,
T. A. Grdina,
J. J. Cohen, and T. S. Dermody.
1995.
Differences in the capacity of reovirus strains to induce apoptosis are determined by viral attachment protein 1.
J. Virol.
69:6972-6979[Abstract].
|
| 70. |
Valentin, H.,
O. Azocar,
B. Horvat,
R. Willeims,
R. Garrone,
A. Evlasher,
M. L. Toribio, and C. Rabourdin-Combe.
1999.
Measles virus infection induces terminal differentiation of human thymic epithelial cells.
J. Virol.
73:2212-2221 |
| 71. | Wang, K. K., R. Postmantur, R. Nadimpalli, R. Nath, P. Mohan, R. A. Nixon, R. V. Talanian, M. Keegan, L. Herzog, and H. Allen. 1998. Caspase-mediated fragmentation of calpain inhibitor protein calpastatin during apoptosis. Arch. Biochem. Biophys. 356:187-196[CrossRef][Medline]. |
| 72. | Wang, K. K. W., and P. Yuen. 1994. Calpain inhibition: an overview of its therapeutic potential. Trends Pharmacol. Sci. 15:412-419[CrossRef][Medline]. |
| 73. |
Watt, F., and P. L. Molloy.
1993.
Specific cleavage of transcription factors by the thiol protease, m-calpain.
Nucleic Acids Res.
21:5092-5100 |
| 74. | Weller, M., J. B. Schulz, U. Wullner, P. A. Loschmann, T. Klockgether, and J. Dichgans. 1997. Developmental and genetic regulation of programmed neuronal death. J. Neural Transm. 50:115-123. |
| 75. | Wood, D. E., A. Thomas, L. A. Devi, Y. Berman, R. C. Beavis, J. C. Reed, and E. W. Newcomb. 1998. Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene 17:1069-1078[CrossRef][Medline]. |
| 76. |
Wood, D. E., and E. W. Newcomb.
1999.
Caspase-dependent activation of calpain during drug-induced apoptosis.
J. Biol. Chem.
274:8309-8315 |
| 77. |
Yang, D.,
J. Yu,
Z. Luo,
C. M. Carthy,
J. E. Wilson,
Z. Liu, and B. M. McManus.
1999.
Viral myocarditis: identification of five differentially expressed genes in coxsackievirus B3-infected mouse heart.
Circ. Res.
84:704-712 |
| 78. |
Yeh, E. T.
1997.
Life and death in the cardiovascular system.
Circulation
95:782-786 |
| 79. | Zhivotovsky, B., D. H. Burgess, D. M. Vanags, and S. Orrenius. 1997. Involvement of cellular proteolytic machinery in apoptosis. Biochem. Biophys. Res. Commun. 230:481-488[CrossRef][Medline]. |
This article has been cited by other articles: